This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Endoplasmic reticulum aminopeptidase 1 (ERAP1; ARTS1; ERAAP); ERAP2; insulin-regulated aminopeptidase (IRAP)	<p><i>In vitro</i> and mouse studies identified inhibitors of ERAP1, ERAP2 and IRAP that could help treat inflammation or cancer. The three enzymes process antigens for presentation on cell surfaces, but overactivity can prevent normal antigen presentation. In HeLa cells, the most potent, competitive pseudo-peptidic inhibitor of the three enzymes increased presentation of a test antigen compared with less potent inhibitors or no inhibitor treatment. In mouse colon carcinoma cells, the inhibitor increased both antigen presentation and a cytotoxic T cell response. Next steps include testing the inhibitors in mouse models of cancer.</p> <p>SciBX 7(2); doi:10.1038/scibx.2014.49 Published online Jan. 16, 2014</p>	Patent application filed; available for licensing	<p>Zervoudi, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Nov. 18, 2013; doi:10.1073/pnas.1309781110 Contact: Efstratios Stratikos, National Center for Scientific Research Demokritos, Agia Paraskevi, Greece e-mail: stratos@rrp.demokritos.gr Contact: Dimitris Georgiadis, National and Kapodistrian University of Athens, Athens, Greece e-mail: dgeorgia@chem.uoa.gr</p>